{"id":71441,"date":"2026-05-20T11:35:00","date_gmt":"2026-05-20T11:35:00","guid":{"rendered":"https:\/\/medsbase.com\/hmg-peptide\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"hmg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/hmg-peptide\/","title":{"rendered":"HMG (Human Menopausal Gonadotropin \/ Menotropin) \u2014 Pharmaceutical Grade"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is HMG (pharmaceutical-grade)?<\/h3>\n<p style=\"margin: 0;\"><strong>HMG<\/strong> (Gonadotropina Menopausale Umana, nota anche come <strong>menotropina<\/strong>; CAS 61489-71-2) \u00e8 una preparazione glicoproteica ormonale derivata dalle urine contenente uguale attivit\u00e0 biologica di LH e FSH (75 UI LH + 75 UI FSH per vial, il rapporto standard 1:1). Purificata dalle urine di donne in postmenopausa \u2014 il cui output di gonadotropine ipofisarie \u00e8 naturalmente elevato dall'assenza di inibizione da feedback negativo \u2014 l'hMG \u00e8 il canonico <strong>doppio agonista LHCGR + FSHR<\/strong> in endocrine pharmacology and the reference tool for protocols that need simultaneous Leydig-cell \/ theca-cell steroidogenesis (LH side) and Sertoli-cell \/ granulosa-cell action (FSH side). The supplied pharmaceutical-grade material is the urinary-extracted glycoform at \u226599% HPLC purity. <em>For clinical studies use only.<\/em> Distinto dalle preparazioni cliniche di menotropina (Menopur, Menogon, Repronex).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe di Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Preparazione di ormoni glicoproteici \u2014 miscela fissa 1:1 di attivit\u00e0 biologica LH e FSH; doppio agonista del recettore LH\/CG (LHCGR) + recettore FSH (FSHR); preparazione di ormoni peptidici<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Chimico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gonadotropina Menopausale Umana (Menotropina; preparazione estratta da urina; sinonimi: hMG, urofollitropina-con-LH, gonadotropina menopausale)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">61489-71-2 (menotropina \/ preparazione mista hMG)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Componenti Attivi<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>LH<\/strong> (ormone luteinizzante, eterodimero ~30 kDa; \u03b1 92 aa + \u03b2 121 aa, glicosilato) \u2014 75 UI per flaconcino; <strong>FSH<\/strong> (ormone follicolo-stimolante, eterodimero ~30 kDa; \u03b1 92 aa + \u03b2 111 aa, glicosilato) \u2014 75 UI per flaconcino. La subunit\u00e0 \u03b1 \u00e8 condivisa tra LH, FSH, HCG e TSH; le subunit\u00e0 \u03b2 conferiscono specificit\u00e0 recettoriale. Entrambe le gonadotropine sono ampiamente N- e O-glicosilate.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rapporto di Bioattivit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Attivit\u00e0 LH:FSH = 1:1 (il rapporto standard dell'hMG dalla standardizzazione della potenza alla fine degli anni '90; entrambe le attivit\u00e0 misurate con il saggio biologico dell'OMS rispetto agli standard di riferimento internazionali)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>HCG Co-Purification (studies-relevant)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Una caratteristica dei preparati di hMG derivati da urina: le analisi compositive pubblicate riportano che circa <strong>il 95% dell'attivit\u00e0 biologica mediata dal recettore LH in vivo \u00e8 attribuibile alla traccia di HCG co-purificata dall'urina postmenopausale<\/strong> (Wolfenson et\u00a0al. 2005 and others). HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h half-life vs LH&#8217;s ~20 min \u2014 so even small HCG amounts dominate the in-vivo LH-equivalent signal. Users should be aware of this when comparing hMG to pure recombinant LH (Luveris) preparations.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Meccanismo d'azione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Doppio agonismo GPCR. <strong>LHCGR<\/strong> (accoppiato a Gs, cellule di Leydig\/teca\/granulosa\/corpo luteo) \u2192 cascata cAMP-PKA-StAR-CYP17A1 \u2192 biosintesi di androgeni. <strong>FSHR<\/strong> (accoppiato a Gs, cellule di Sertoli nei maschi\/cellule della granulosa nelle femmine) \u2192 cascata cAMP-PKA-CYP19A1\/aromatasi \u2192 supporto alla spermatogenesi (maschio) o conversione di androgeni in estrogeni + maturazione follicolare (femmina). La doppia attivazione \u00e8 ci\u00f2 che distingue l'hMG dai preparati di LH puro (Luveris\/rLH) o FSH puro (Gonal-F\/Puregon\/rFSH).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Preparato misto \u2014 sia LH che FSH sono glicoproteine eterodimeriche. Subunit\u00e0 \u03b1 (condivisa) ~92 aa, identica tra LH\/FSH\/HCG\/TSH. Subunit\u00e0 \u03b2 dell'LH ~121 aa, subunit\u00e0 \u03b2 dell'FSH ~111 aa. Le sequenze complete sono disponibili su UniProt: LH\u03b2 (P01229), FSH\u03b2 (P01225), GPH\u03b1 (P01215).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formula Molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Preparato glicoproteico estratto da urina \u2014 FSH (\u03b1 92aa + \u03b2 111aa) + LH (\u03b1 92aa + \u03b2 121aa) eterodimeri in rapporto di attivit\u00e0 biologica ~1:1. Nessuna formula molecolare singola a causa del pattern eterogeneo di glicosilazione nel preparato.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Emivita plasmatica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Attivit\u00e0 FSH: emivita terminale ~30-40 h (guidata dalla sialilazione, simile ad altri ormoni glicoproteici). Attivit\u00e0 LH nell'hMG: nominalmente ~10-20 h (ma in pratica guidata dalla frazione di HCG co-purificata con emivita di 33-37 h \u2014 vedi nota sulla co-purificazione di HCG sopra).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder with mannitol or lactose stabilising matrix; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificato con HPLC); il saggio biologico dell'OMS conferma l'attivit\u00e0 di LH e FSH alla dose etichettata di 75 IU ciascuno. Certificato di analisi disponibile su richiesta.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Ricostituire in acqua batteriostatica a 1,0 mL per flaconcino \u2192 75 IU di LH + 75 IU di FSH per mL di soluzione di lavoro; altre diluizioni secondo protocollo. Il liofilizzato si scioglie rapidamente con un delicato movimento rotatorio. <strong>Non agitare; non utilizzare il vortex<\/strong> \u2014 la miscelazione ad alta forza di taglio dissocia gli eterodimeri \u03b1\/\u03b2 sia della componente LH che della FSH.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138 \u00b0C se non aperto per la soluzione di lavoro a breve termine; \u221220 \u00b0C per lo stoccaggio a lungo termine (stabile \u226536 mesi a \u221220 \u00b0C; \u226518 mesi a 2\u20138 \u00b0C). Ricostituito: 2\u20138 \u00b0C, utilizzare entro ~30 giorni. Proteggere dalla luce. <strong>Non congelare il materiale ricostituito<\/strong> \u2014 i cicli di congelamento-scongelamento dissociano gli eterodimeri \u03b1\/\u03b2 di LH e FSH e distruggono la bioattivit\u00e0.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 l'HMG (Menotropina)?<\/h2>\n<p><strong>HMG<\/strong> \u2014 Gonadotropina Menopausale Umana, anche conosciuta come <strong>menotropina<\/strong> (CAS 61489-71-2) \u2014 is a urinary-derived glycoprotein-hormone preparation containing equal amounts of LH (luteinising hormone) and FSH (follicle-stimulating hormone) bioactivity, standardised at 75 IU of each per vial. It is purified by ion-exchange and gel-filtration chromatography from the pooled urine of postmenopausal women, who have naturally elevated pituitary gonadotropin output (LH and FSH typically 50\u2013100+ mIU\/mL each) due to the loss of ovarian negative-feedback inhibition that accompanies menopause. The &#8220;menopausal&#8221; in the name refers to this source: postmenopausal urine is the most concentrated natural source of LH and FSH available for industrial-scale purification, and hMG has been produced from this source since the early 1960s (the original Cesare Serono-developed Pergonal preparation). The compositional refinement of hMG has evolved substantially over the decades \u2014 earlier preparations had highly variable LH:FSH ratios and significant protein-impurity loads; modern preparations (the basis of our pharmaceutical-grade material) are standardised at 75:75 IU bioactivity per vial with \u226599% HPLC purity. hMG is the canonical dual-gonadotropin pharmacological tool. Where HCG selectively activates the LHCGR, where pure-LH (recombinant Luveris) selectively activates the LHCGR at physiological half-life, where pure-FSH (recombinant Gonal-F \/ Puregon) selectively activates the FSHR, hMG activates both receptors simultaneously at a fixed 1:1 ratio. The two receptors are expressed on different cell populations within the gonad \u2014 LHCGR on Leydig cells \/ theca cells \/ luteinised granulosa \/ corpus luteum; FSHR on Sertoli cells \/ mural granulosa \u2014 so dual activation produces a complete physiological gonadotropin stimulus that more closely mimics endogenous mid-cycle pituitary output than either receptor activated alone. <strong>A studies-relevant nuance: HCG co-purification.<\/strong> Published compositional analyses of urinary-derived hMG preparations report that the bulk of the in-vivo LH-receptor bioactivity is actually attributable to trace HCG co-purified from postmenopausal urine \u2014 approximately 95% of LH-receptor-mediated bioactivity by some analyses (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life versus LH&#8217;s ~20 min, so even small HCG amounts dominate the cumulative in-vivo LH-equivalent signal. This is part of why hMG produces sustained Leydig-cell stimulation despite the nominal &#8220;LH activity&#8221; of LH itself being short-lived. For protocols where this distinction matters (pure-LH pharmacology vs HCG-contaminated mixed-LH signal), recombinant LH (Luveris) is the cleaner tool; for protocols where dual LHCGR + FSHR activation at physiological 1:1 ratio is the goal, hMG is the canonical reference. <\/p>\n<h2>Meccanismo d'azione \u2014 Attivazione duale di LHCGR + FSHR<\/h2>\n<p>Il meccanismo dell'hMG \u00e8 la somma duale delle sue due attivit\u00e0 componenti, entrambe ben caratterizzate in farmacologia endocrina:<\/p>\n<ul>\n<li><strong>LH (e HCG co-purificato) \u2192 attivazione di LHCGR<\/strong> \u2014 La componente LH (e le tracce di HCG che si co-purificano dall'urina postmenopausale) si lega al recettore LH\/CG sulle cellule di Leydig (testicolo) e sulle cellule della teca\/granulosa\/luteali (ovaio). L'accoppiamento a Gs aumenta il cAMP, attiva la PKA, regola positivamente il trasporto mitocondriale del colesterolo mediato da StAR e induce gli enzimi steroidogenici CYP11A1\/CYP17A1\/3\u03b2-HSD\/17\u03b2-HSD \u2014 guidando la biosintesi de novo del testosterone (maschio) o dell'androstenedione (femmina).<\/li>\n<li><strong>FSH \u2192 attivazione di FSHR<\/strong> \u2014 La componente FSH si lega al recettore FSH sulle cellule di Sertoli (testicolo) e sulle cellule della granulosa murale (ovaio). Anche FSHR \u00e8 accoppiato a Gs, ma il suo programma a valle \u00e8 distinto: nelle cellule di Sertoli l'attivazione di FSHR promuove la produzione di proteina legante gli androgeni (ABP), inibina B e il programma di supporto strutturale che sostiene la spermatogenesi; nelle cellule della granulosa l'attivazione di FSHR stimola CYP19A1 (aromatasi), convertendo gli androgeni derivati dalle cellule della teca in estrogeni, e promuove la maturazione follicolare attraverso gli stadi antrali e pre-ovulatori.<\/li>\n<li><strong>Modello combinato a due cellule e due gonadotropine<\/strong> \u2014 Il classico quadro endocrino. Nel testicolo maschile, le cellule di Leydig stimolate da LH producono testosterone, che diffonde nelle adiacenti cellule di Sertoli dove la proteina legante gli androgeni indotta da FSH e la macchina metabolica delle cellule di Sertoli lo convertono nel microambiente ad alto testosterone intratesticolare richiesto per la spermatogenesi. Nell'ovaio femminile, le cellule della teca stimolate da LH producono androgeni, che diffondono nelle adiacenti cellule della granulosa dove l'aromatasi indotta da FSH li converte in estrogeni. Il modello a due cellule e due gonadotropine \u00e8 il quadro canonico, e l'hMG \u00e8 lo strumento farmacologico canonico per coinvolgere simultaneamente entrambe le met\u00e0.<\/li>\n<li><strong>Desensibilizzazione recettoriale e tachifilassi<\/strong> \u2014 Both LHCGR and FSHR undergo arrestin-mediated desensitization after sustained agonist exposure. Repeated high-dose hMG dosing can produce receptor downregulation \u2014 a well-documented phenomenon in published gonadotropin-pharmacology studies relevant to chronic-dosing protocols.<\/li>\n<li><strong>Feedback ipotalamo-ipofisario<\/strong> \u2014 As with HCG, hMG-driven gonadal steroid output feeds back to the hypothalamus and pituitary to suppress endogenous GnRH and LH\/FSH secretion. In the context of HPG-suppression studies (testosterone replacement, AAS exposure, pharmacological GnRH antagonism), hMG bypasses the hypothalamic-pituitary blockade by acting directly at the gonadal receptors \u2014 preserving both Leydig-cell function (LH side) and Sertoli-cell \/ spermatogenesis-support function (FSH side) simultaneously, which is what distinguishes hMG from pure-HCG protocols in this context.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of hMG broadly mirrors that of its components: FSH activity persists with 30\u201340 h terminal half-life, LH-equivalent activity is dominated by the long-half-life co-purified HCG (33\u201337 h), and the combined preparation produces sustained 24\u201372 h dual gonadotropin stimulation per dose. Typical protocol dosing is 75\u2013225 IU SC daily in rodent or human-subject studies \u2014 equivalent to 1\u20133 vials of the 75 IU strength. <\/p>\n<h2>Published Evidence<\/h2>\n<p>hMG is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia delle gonadotropine \u2014 il riferimento canonico per il dualismo recettoriale<\/strong> \u2014 most-cited dual LHCGR + FSHR agonist in published gonadotropin studies; standard reference compound for dissecting LH-only vs FSH-only vs combined gonadotropin signalling<\/li>\n<li><strong>Spermatogenesis induction studies<\/strong> \u2014 in hypogonadotropic-hypogonadism rodent models, hMG (with or without supplementary HCG) is the canonical tool for inducing spermatogenesis by restoring both Leydig-cell testosterone production and Sertoli-cell FSH support; standard protocol cycle is 75\u2013150 IU SC three times per week for 6\u201324 months in clinical-translational studies<\/li>\n<li><strong>Female ovarian-stimulation studies<\/strong> \u2014 the historical foundation tool of in-vitro fertilisation studies; hMG drives follicular development through the antral and pre-ovulatory stages in published ovulation-induction protocols, typically combined with HCG as ovulation trigger; widely used in studies on polycystic ovary syndrome (PCOS), unexplained infertility, and assisted reproductive technologies<\/li>\n<li><strong>Two-cell two-gonadotropin model studies<\/strong> \u2014 the canonical framework of gonadal steroidogenesis pharmacology; hMG is the standard tool for activating both halves of the model simultaneously; published Sertoli-Leydig co-culture and theca-granulosa co-culture uses hMG to recapitulate the physiological dual-receptor stimulus<\/li>\n<li><strong>HPG-axis suppression-recovery<\/strong> \u2014 in published studies models where endogenous LH\/FSH has been suppressed (by exogenous testosterone, AAS exposure, or GnRH antagonism), hMG preserves both Leydig-cell function and Sertoli-cell function by direct gonadal receptor activation \u2014 distinguishing it from HCG-only protocols which preserve only LH-side function and risk Sertoli-cell atrophy<\/li>\n<li><strong>Farmacologia comparativa vs LH puro \/ FSH puro \/ HCG<\/strong> \u2014 i confronti testa a testa pubblicati tra hMG e LH ricombinante (Luveris), FSH ricombinante (Gonal-F \/ Puregon), HCG ricombinante (Ovidrel) e varie combinazioni sono ampi; l'hMG \u00e8 il riferimento misto 1:1 di derivazione urinaria rispetto al quale tutti questi vengono valutati<\/li>\n<li><strong>Sviluppo follicolare e biologia delle cellule della granulosa<\/strong> \u2014 published ex-vivo follicular culture and primary granulosa-cell uses hMG to drive simultaneous theca-cell androgen production and granulosa-cell aromatase induction \u2014 the most physiologically relevant in-vitro stimulus available<\/li>\n<li><strong>Biologia del corpo luteo<\/strong> \u2014 sustained LHCGR activation by the LH component (and co-purified HCG) maintains corpus-luteum function and progesterone production; used in studies on the luteal phase and luteo-placental transition<\/li>\n<\/ul>\n<p>For broader context on HPG-axis and reproductive-system peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/it\/hcg-peptide\/\">HCG (Gonadotropina Corionica Umana)<\/a> (agonista puro del LHCGR \u2014 confronto diretto; solo attivit\u00e0 lato LH), <a href=\"https:\/\/medsbase.com\/it\/kisspeptin-10\/\">Kisspeptina-10<\/a> (agonista del Kiss1R ipotalamico \u2014 guida la pulsativit\u00e0 endogena del GnRH), <a href=\"https:\/\/medsbase.com\/it\/pt-141\/\">PT-141 (Bremelanotide)<\/a> (melanocortin-receptor pharmacology \u2014 sexual-function studies), and <a href=\"https:\/\/medsbase.com\/it\/oxytocin-acetate\/\">Ossitocina Acetato<\/a> (ormone peptidico della neuroipofisi). Esplora l'intero <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">peptides &amp; compounds catalog<\/a>. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks HMG (urinary-extracted menotropin) in a single lyophilized vial strength calibrated to the standard 1:1 LH:FSH bioactivity unit. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosaggio per Flaconcino<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>75 IU LH + 75 IU FSH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength (the international-reference unit dose) \u2014 single-dose dual-gonadotropin stimulation, spermatogenesis-induction protocols (75\u2013225 IU SC three times per week), ovarian-stimulation studies, two-cell two-gonadotropin co-culture stimulation, comparative pharmacology vs recombinant pure-LH and pure-FSH preparations<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 75:75 IU vial is the international-reference dose unit and the format used in essentially all published gonadotropin studies and clinical practice. Multiple-vial dosing (150 IU, 225 IU per administration) is standard for higher-dose protocols. The 30-vial pack is the more economical purchase per-IU for extended-cycle or multi-cohort protocols. <\/p>\n<h2>Confronto \u2014 HMG vs HCG<\/h2>\n<p><a href=\"https:\/\/medsbase.com\/it\/hcg-peptide\/\">HCG<\/a> e hMG sono i due preparati gonadotropinici derivati dall'urina presenti in questo catalogo, e agiscono sul sistema dei recettori gonadotropinici in modi meccanicamente distinti. HCG \u00e8 un <em>puro<\/em> agonista del recettore LH\/CG \u2014 attivazione solo delle cellule di Leydig \/ cellule della teca. hMG \u00e8 il preparato <em>duale<\/em> LH + FSH preparation \u2014 engages both halves of the two-cell two-gonadotropin model simultaneously. The choice between them in studies depends on whether the protocol needs LH-side activation alone or combined LH-side + FSH-side activation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HMG (Menotropina)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HCG<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composizione<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Miscela fissa 1:1: LH 75 UI + FSH 75 UI per flaconcino (+ tracce di HCG che dominano il segnale equivalente LH in vivo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">HCG puro (estratto dall'urina) \u2014 singola glicoproteina<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Recettori coinvolti<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR <em>e<\/em> FSHR \u2014 attivazione duale del recettore delle gonadotropine<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR solo \u2014 singolo recettore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Source<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urina postmenopausale<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urina di donne in gravidanza (uHCG) o cellule CHO ricombinanti (rHCG)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Spermatogenesis induction (preserves Sertoli-cell function), ovarian follicular stimulation, two-cell two-gonadotropin model studies, dual-receptor pharmacology<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Leydig-cell-only stimulation, ovulation triggering (LH-surge mimic), Leydig-cell-specific HPG-suppression-recovery, LHCGR pharmacology<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Emivita plasmatica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FSH ~30\u201340 h; attivit\u00e0 equivalente a LH dominata da HCG co-purificato (33\u201337 h)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">33\u201337 h (fase terminale)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosaggio tipico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75\u2013225 UI SC (1\u20133 flaconcini) per somministrazione; 3\u00d7\/settimana nei protocolli cronici<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">500\u20135.000 UI SC\/IM (singolo bolo); 250\u2013500 UI\/giorno nei protocolli cronici<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Unit\u00e0 di dosaggio in flaconcino<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75 UI di bioattivit\u00e0 (dose unitaria di riferimento internazionale)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5.000 o 10.000 UI di bioattivit\u00e0<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Stato WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Vietato in ogni momento per gli atleti maschi (S2 \u2014 Ormoni peptidici)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Vietato in ogni momento agli atleti maschi (S2 \u2014 Ormoni peptidici); esenzione per atlete donne<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on dual LHCGR + FSHR activation, spermatogenesis induction, or the canonical two-cell two-gonadotropin model, hMG is the standard reference compound. For studies focused on Leydig-cell-only stimulation, ovulation triggering, or HCG-specific LHCGR pharmacology, <a href=\"https:\/\/medsbase.com\/it\/hcg-peptide\/\">HCG<\/a> \u00e8 lo strumento pi\u00f9 mirato. Vedi anche <a href=\"https:\/\/medsbase.com\/it\/kisspeptin-10\/\">Kisspeptina-10<\/a> for upstream hypothalamic Kiss1R \/ GnRH-pulsatility studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Hai bisogno di acqua BAC?<\/strong> La ricostituzione di qualsiasi flaconcino liofilizzato richiede acqua sterile batteriostatica. Abbina questo prodotto al nostro <a href=\"\/it\/bac-water\/\"><strong>BAC Water (Acqua Batteriostatica)<\/strong><\/a> \u2014 flaconcino multidose da 30 mL, conservato con alcool benzilico 0,9%, grado USP.<\/div>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare i flaconcini liofilizzati refrigerati a 2\u20138 \u00b0C nella confezione originale per le scorte di lavoro a breve termine. Per lo stoccaggio a lungo termine, congelare i flaconcini non aperti a \u221220 \u00b0C (stabile \u226536 mesi a \u221220 \u00b0C; \u226518 mesi a 2\u20138 \u00b0C). La polvere liofilizzata \u00e8 stabilizzata con mannitolo o lattosio e tollera ragionevolmente brevi esposizioni a temperatura ambiente durante la manipolazione, ma deve essere riportata in frigorifero prontamente. Proteggere dalla luce. <strong>Procedura di ricostituzione:<\/strong> for each 75 IU vial, inject 1.0\u00a0mL of bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake) \u2014 this yields a working stock of 75 IU LH + 75 IU FSH per mL. For protocols that need higher concentrations (multi-vial pooling for higher single-dose), reconstitute 2\u20133 vials with the same 1.0\u00a0mL diluent total to give 150\u2013225 IU\/mL. <strong>Agitare delicatamente per sciogliere \u2014 non scuotere, non usare il vortex.<\/strong> La miscelazione ad alto taglio dissocia gli eterodimeri \u03b1\/\u03b2 sia dei componenti LH che FSH e distrugge la bioattivit\u00e0 del recettore delle gonadotropine. La polvere liofilizzata a base di mannitolo di solito si scioglie entro 30\u201360 secondi con un delicato agitamento. <strong>Regole critiche di conservazione per il materiale ricostituito:<\/strong> una volta ricostituito, conservare a 2\u20138 \u00b0C e utilizzare entro 30 giorni. <strong>Non congelare l'hMG ricostituito<\/strong> \u2014 freeze-thaw cycles dissociate the LH and FSH \u03b1\/\u03b2 heterodimers (the same physical-chemistry constraint as HCG) and irreversibly destroy bioactivity. Protect from light. Discard if cloudiness, particulates, or marked colour change appears. For protocols requiring multiple aliquots, prepare aliquots at the time of reconstitution and store at 2\u20138 \u00b0C separately rather than freezing. <\/p>\n<h2>Domande frequenti<\/h2>\n<h3>Qual \u00e8 la differenza tra HMG e HCG?<\/h3>\n<p><a href=\"https:\/\/medsbase.com\/it\/hcg-peptide\/\">HCG<\/a> is a pure LH\/CG-receptor agonist \u2014 single glycoprotein hormone (CAS 9002-61-3) that binds and activates only the LHCGR on Leydig \/ theca \/ granulosa \/ luteal cells. hMG is a 1:1 mixture of LH and FSH bioactivity \u2014 distinct glycoprotein hormones (combined CAS 61489-71-2) that bind both the LHCGR (LH side) and the FSHR (FSH side). The clinical and studies consequence is that hMG produces dual-receptor stimulation that engages both halves of the two-cell two-gonadotropin model (Leydig + Sertoli in males; theca + granulosa in females), where HCG produces single-receptor stimulation of the LHCGR side only. <\/p>\n<h3>What is the HCG co-purification in hMG, and why does it matter for studies?<\/h3>\n<p>Le analisi compositive pubblicate dei preparati di hMG derivati dalle urine riportano che approssimativamente <strong>Il 95% della bioattivit\u00e0 mediata dal recettore LH in vivo<\/strong> is actually attributable to trace HCG co-purified from postmenopausal urine, rather than to LH itself (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life vs LH&#8217;s ~20 min \u2014 so even small amounts of co-purified HCG dominate the cumulative in-vivo LH-equivalent signal. For protocols where this distinction matters (e.g., comparing pure-LH pharmacology vs HCG-contaminated mixed-LH signal), <strong>l'LH ricombinante (Luveris)<\/strong> \u00e8 lo strumento pi\u00f9 pulito. Per i protocolli in cui l'attivazione duale di LHCGR + FSHR in un rapporto fisso 1:1 \u00e8 l'obiettivo, l'hMG \u00e8 il riferimento canonico. <\/p>\n<h3>Perch\u00e9 l'hMG \u00e8 ottenuto dalle urine di donne postmenopausali?<\/h3>\n<p>Le donne postmenopausali perdono l'inibizione a feedback negativo ovarico sull'asse ipotalamo-ipofisario, il che aumenta drasticamente la produzione di LH e FSH ipofisari \u2014 i tipici livelli sierici di LH e FSH postmenopausali sono di 50\u2013100+ mIU\/mL ciascuno, un ordine di grandezza superiore rispetto ai valori premopausali. Entrambi gli ormoni vengono poi eliminati per via renale nelle urine in forma concentrata. Pertanto, le urine postmenopausali raccolte rappresentano la fonte naturale pi\u00f9 concentrata di LH + FSH per l'estrazione su scala industriale. L'industria dell'hMG \u00e8 stata costruita su questa intuizione nei primi anni '60 (Pergonal era la preparazione originale della Serono) e continua ancora oggi, sebbene gran parte del mercato clinico si sia spostato verso preparazioni ricombinanti di LH puro e FSH puro. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>Single-dose protocol use is typically 75\u2013225 IU SC per administration (1\u20133 vials of the 75 IU strength), with 3\u00d7\/week or daily dosing in chronic protocols. Spermatogenesis-induction protocols in published hypogonadotropic-hypogonadism studies typically use 75\u2013150 IU 3\u00d7\/week for 6\u201324 months in combination with HCG (the HCG provides additional Leydig-cell stimulation). In-vitro Sertoli-cell or granulosa-cell culture protocols typically use 1\u201310 IU\/mL in growth medium. Users should consult primary literature appropriate to the species, model, and endpoint. <\/p>\n<h3>Qual \u00e8 la differenza tra hMG e FSH ricombinante puro (Gonal-F \/ Puregon)?<\/h3>\n<p>L'FSH ricombinante puro (follitropina alfa \/ Gonal-F; follitropina beta \/ Puregon; prodotto in cellule CHO da cDNA clonati di FSH \u03b1 e \u03b2) contiene <em>solo<\/em> FSH bioactivity \u2014 no LH, no HCG. hMG contains both LH and FSH bioactivity at 1:1 ratio (plus trace HCG). For protocols that need pure FSHR activation isolated from LHCGR signalling, recombinant FSH is the correct tool. For protocols that need combined dual-receptor activation at physiological ratio, hMG is the correct tool. Published head-to-head trials in ovarian-stimulation have compared the two with broadly equivalent follicular-development endpoints but with subtly different oestradiol-response profiles (hMG tends to produce slightly higher mid-cycle oestradiol due to the LH-side androgen substrate it provides for granulosa-cell aromatase). <\/p>\n<h3>Perch\u00e9 l'hMG ricostituito non pu\u00f2 essere congelato?<\/h3>\n<p>La stessa ragione dell'HCG \u2014 sia LH che FSH sono eterodimeri composti da due subunit\u00e0 associate non covalentemente (\u03b1 + \u03b2 ciascuna). L'interazione \u03b1\/\u03b2 \u00e8 stabile nella polvere liofilizzata (nessuna acqua per interrompere l'interazione) e stabile in soluzione acquosa refrigerata a 2\u20138 \u00b0C (la cinetica di dissociazione \u00e8 lenta a basse temperature). Ma la formazione di cristalli di ghiaccio durante il congelamento separa fisicamente le subunit\u00e0, che si riassociano solo inefficientemente allo scongelamento. Il risultato \u00e8 che l'hMG congelato e scongelato conserva una grande frazione di immunoreattivit\u00e0 ma perde una grande frazione di bioattivit\u00e0. L'hMG liofilizzato pu\u00f2 essere congelato ed \u00e8 stabile a \u221220 \u00b0C; l'hMG ricostituito no. <\/p>\n<h3>Qual \u00e8 lo status normativo WADA dell'hMG?<\/h3>\n<p>hMG \/ menotropin is on the World Anti-Doping Agency (WADA) Prohibited List under class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times \u2014 both in-competition and out-of-competition \u2014 for male athletes. Users conducting human-subject studies with hMG need to be aware of this regulatory status. For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>How does this pharmaceutical-grade hMG compare with the branded clinical preparations (Menopur, Menogon, Repronex)?<\/h3>\n<p>The branded clinical preparations are urinary-extracted menotropin (Menopur, Menogon, Repronex; the historical Pergonal preparation has been largely discontinued) packaged under various manufacturer SKUs for clinical use in assisted reproductive technologies. The pharmaceutical-grade hMG supplied here is the same urinary-extracted preparation at \u226599% HPLC purity, supplied without a clinical-use label and intended for clinical studies only. Users seeking clinical-use menotropin should obtain it through a clinical supply chain; users seeking pharmaceutical-grade material for in-vitro receptor pharmacology, rodent in-vivo work, or other clinical applications can use the material supplied here. <\/p>\n<h3>Can hMG be combined with HCG, Kisspeptin-10, or testosterone in protocols?<\/h3>\n<p>Yes \u2014 these compounds target different layers of the HPG axis and are commonly combined in published studies. The most-published combinations are hMG + HCG (the standard clinical and protocol for spermatogenesis induction in hypogonadotropic-hypogonadism models \u2014 hMG provides FSH-side support, additional HCG provides supplemental LH-side stimulation); hMG + <a href=\"https:\/\/medsbase.com\/it\/kisspeptin-10\/\">Kisspeptina-10<\/a> (upstream + downstream dissection \u2014 kisspeptin drives endogenous GnRH while hMG provides direct gonadal stimulation); hMG + exogenous testosterone (for HPG-suppression-recovery, where the testosterone suppresses endogenous LH\/FSH and hMG bypasses the suppression by acting directly at the gonad). Reconstitute each separately and follow each compound&#8217;s specific storage rules \u2014 neither hMG nor HCG should be frozen reconstituted. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HPG-Axis and Reproductive Studies<\/h2>\n<ul>\n<li><a href=\"\/it\/hcg-peptide\/\"><strong>HCG (Gonadotropina Corionica Umana)<\/strong><\/a> \u2014 Agonista puro del recettore LH\/CG \u2014 confronto diretto; attivit\u00e0 solo sul lato LH<\/li>\n<li><a href=\"\/it\/kisspeptin-10\/\"><strong>Kisspeptina-10<\/strong><\/a> \u2014 Agonista Kiss1R ipotalamico \u2014 regolatore a monte dell'asse HPG, stimola la pulsatilit\u00e0 del GnRH<\/li>\n<li><a href=\"\/it\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Melanocortin-4 receptor agonist \u2014 sexual-function studies<\/li>\n<li><a href=\"\/it\/oxytocin-acetate\/\"><strong>Ossitocina Acetato<\/strong><\/a> \u2014 Posterior pituitary nonapeptide \u2014 reproductive and social bonding<\/li>\n<li><a href=\"\/it\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 Analogico del GHRH \u2014 asse endocrino diverso, comunemente studiato in combinazione<\/li>\n<li><a href=\"\/it\/bac-water\/\"><strong>BAC Water (Acqua Batteriostatica)<\/strong><\/a> \u2014 Necessario per ricostituire qualsiasi flaconcino liofilizzato \u2014 diluente sterile, conservato con alcol benzilico 0,9%<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Preparazione glicoproteica duale LH + FSH \u2014 rapporto di bioattivit\u00e0 1:1 (75 UI ciascuno)<br \/>\n\u2705 Agonista canonico duale dei recettori gonadotropinici LHCGR + FSHR<br \/>\n\u2705 Menotropina estratta da urina di donne in postmenopausa (CAS 61489-71-2)<br \/>\n\u2705 Modello a due cellule e due gonadotropine \u2014 coinvolge cellule di Leydig+Sertoli o teca+granulosa<br \/>\n\u2705 Standard tool for spermatogenesis-induction &amp; ovarian-stimulation studies<\/p>\n<p><strong>HMG (Pharmaceutical Grade)<\/strong> contiene Menotropina Umana estratta da urina (menotropina).<\/p>","protected":false},"featured_media":71453,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6490,6495,6492,6497,6498,6496,6493,6494],"class_list":["post-71441","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gonadotropin","product_tag-hmg","product_tag-hpg-axis","product_tag-human-menopausal-gonadotropin","product_tag-lhcgr-fshr-agonist","product_tag-menotropin","product_tag-reproductive-research","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/71441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=71441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/71453"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=71441"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=71441"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=71441"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=71441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}